RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has announced compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases, successfully maintained a minimum closing bid price of $1.00 per share for its American Depositary Shares over 10 consecutive business days. RedHill Biopharma’s key late-stage development programs include treatments for COVID-19 and various gastrointestinal diseases.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
